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ABSTRACT
Hyponatraemia is an electrolyte disorder, 
defined as a serum sodium concentration 
(Na) <136 mmol/L. It occurs in up to 30% 
of hospitalised patients. The purpose of 
this study was to evaluate the frequency of 
hyponatraemia among all patients during 
a one month period in the emergency unit. 
During the one month period in 2014, 570 
patients were included in this study. The 
study was approved by local ethics com-
mittees and patients provided written in-
formed consent. 
Out of the 570 patients, 41 (7%) had hy-
ponatraemia. The median age was 67 
(65.02±14.09) years and the majority 
of the patients were men (M:F = 23:18; 
56.1:43.9%). Mild hyponatraemia (serum 
Na 130-135 mmol/L) was found in 71% 
(29/41), moderate (serum Na 125-129 
mmol/L) in 17% (7/41), severe (serum Na 
120-124 mmol/L) in 5% (2/41), and ex-
tremely severe (serum Na< 120 mmol/L) 
in 7% (3/41) of patients. The treatment 
options included the restriction of fluid 
intake by administering hypertonic saline 
and loop diuretics. 
We should be alert to acute hyponatraemia, 
especially in elderly patients with neuro-
logical manifestations and poor progno-
sis. The presented data are an important 
contribution to the better understanding 
of the epidemiology of hyponatraemia  in 
Croatia. 
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INTRODUCTION
Hyponatraemia is the most common dis-
order of electrolyte balance. It occurs in up 
to 30% of hospitalised patients and leads 
to a wide spectrum of symptoms, some 
even life threatening. (1) It is associated 
with increases in both mortality and du-
ration of hospital stay. Hyponatraemia is 
an electrolyte disorder defined as a serum 
sodium concentration (Na) <136 mmol/L 
and is present on admission in 14.5% of all 
patients and in 15-20% of emergency hos-
pital admissions. (1-3)
The early symptoms of hyponatraemia are 
vague and nonspecific, and may mimic 
the symptoms of a psychiatric disorder. 
The most common symptoms are nau-
sea, drowsiness, headache, anorexia, and 
weight gain. These symptoms may be ac-
companied confusion, convulsions, coma 
and death. (2)
A group of patients with hyponatraemia is 
highly risky and hyponatraemia is recog-
nized as a marker of increased risk of de-
veloping comorbidity and as a predictor of 
adverse outcome. (4-6) 
The etiopathogenesis of hyponatraemia 
depends on the underlying disease or 
condition causing it. The most important 
factor in approaching a patient with hy-
ponatraemia is an estimate of the volume 
status (distinguish between hypovolemia, 
hypervolemia and euvolemia). Euvolemia 
is predominantly caused by different drugs 
and inappropriate antidiuretic hormone 
secretion (SIADH), which is often not 
recognized. (3) Many conditions are as-
sociated with SIADH, and they can be 
classified into five main causes: neoplasia, 
hormonal disturbances, non-malignant 
lung disease (pneumonia, tuberculosis, 
asthma, abscesses), iatrogenic (due to tak-
ing a number of different drugs) and other 
(neurological diseases, prolonged physical 
activity, associated with AIDS, persistent 
vomiting, idiopathic in the elderly). (3) 
Hyponatraemia induced by drugs (anti-
inflammatory, diuretics, acetaminophen, 
antipsychotic, haloperidol, amitriptyline, 
fluoxetine) or tumours have incidence up 
to 30% (tumours of the lung, pancreas, 
thyroid). (7, 8) 
The management of patients with hy-
ponatraemia remains very problematic. 
There is a lack of clinical research regard-
ing patients with hyponatraemia in emer-
gency departments.
The purpose of this study was to evaluate 
the frequency of hyponatraemia among all 




The aim of this study was to determine the 
incidence of hyponatraemia in patients 
examined in an emergency department’s 
(ED) internal medicine unit during a one-
month period from December 1, through 
December 31, 2014. Five hundred and 
seventy patients from the Emergency Unit 
Internal Department were included. 
Hyponatraemia is defined as a plasma so-
dium concentration (Na) lower than 136 
mmol per litre. 
Patients with a reduced level of plasma 
sodium concentration were divided into 
four groups depending on the severity of 
hyponatraemia (3): 
1) Group with mild hyponatraemia, de-
fined as a plasma sodium concentration 
between 130-135 mmol per litre (Na level 
of 130-135 mmol/L), 
2) Group with moderately severe hy-
ponatraemia, defined as a plasma sodium 
concentration between 125-129 mmol per 
litre (Na level of 125-129 mmol/L), 
3) Group with severe hyponatraemia, de-
fined as a plasma sodium concentration 
between 120-124 mmol per litre (Na level 
of 120- 124 mmol /L), 
4) Group with extremely severe hy-
ponatraemia, defined as a plasma sodium 
concentration below 120 mmol per litre 
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(level Na <120 mmol/L).
Most patients did not have a certain level 
of sodium in one-time urine (prior to in-
fusion) or plasma/urine osmolality, so the 
same was not taken into analysis. 
A chronic condition of low level of plas-
ma sodium concentration (chronic hy-
ponatraemia) was defined as a duration of 
more than 12 hours. 
Acute hyponatraemia was defined as a 
duration of hyponatraemia of less than 12 
hours.
We investigated the connection between 
the cause and severity of hyponatraemia 
with clinical outcomes of patients (im-
proved, unchanged, death). Date were 
analyzed using SPSS16 software and CHI-
square test, considered statistically signifi-
cant if P < 0.05. The study was approved 
by local ethic committees and patients 
provided written informed consent to par-
ticipate.
RESULTS
The patients were an average age of 65.02 
± 14.09 years, equal distribution between 
the sexes (M/F = 23/18; 56.1% / 43.9%), 
and 7% of patients had some form of hy-
ponatraemia (41/570). Statistically there 
was more mild hyponatraemia (29/41; 
71%) compared to the others (moderately 
severe (7/41; 17%), severe (2/41, 5%) and 
extremely severe (3/41; 7%) hyponatrae-
mia) with p <0.05. The majority of patients 
had a chronic condition of low levels of 
plasma sodium concentration (more than 
12 hours) with symptoms of headache, 
nausea, vomiting and disorientation. The 
most frequent degree of hyponatraemia 
was mild (group 1) and most present in 
cardiac patients and iatrogenic caused by 
diuretic therapy (11/29, 38%), as compared 
to patients with malignant disease (6/29, 
21%), infectious conditions in patients 
with pulmonary and/or endocrinologi-
cal diseases (5/29, 17%), in patients with 
uncontrolled diabetes (3/29, 10%), de-
compensated cirrhosis with complications 
(3/29, 10%), and due to bleeding from 
stomach ulcers (1/29; 4%). 
Moderate hyponatraemia (group 2) was 
most common in patients with dissemi-
nated malignant disease (3/7, 43%), as well 
as in patients with diabetes and hyperten-
sion treated with gentamicin (1/3, 33%) or 
a combination of furosemide and spirono-
lactone (2/3, 67%). The most rare case was 
seen in a patient with chronic kidney dis-
ease (CKD) with hypovolemia (1/7, 14%).
Severe hyponatraemia (group 3) was regis-
tered in patients with uncontrolled endo-
crine diseases (Addison, diabetes mellitus 
type 2) in the state of an infectious disease-
viral and/or bacterial (urosepsis, entero-
colitis). Extremely severe hyponatraemia 
(group 4) was registered in cardiac patients 
with severe aortal stenosis and cardiomyo-
pathies (2/3, 67%). In half of the patients 
with hyponatraemia improvement of the 
situation was achieved (22/41, 54%). A 
third remained constant (14/41, 34%), 
while 12% did not survive the disease 
(5/41). 
Among patients who developed neuro-
logical complications, 80% did not survive 
(94% had acute hyponatraemia). Patients 
with hyponatraemia in ED were treated 
with hypertonic solutions of NaCl (to raise 
serum Na 1-2 mmol/L/hour) along with 
an individual adaptation of the therapeu-
tic approach. Hyponatraemia was not suf-
ficiently treated in 80% patients during the 
later treatment.
DISCUSSION 
Despite the well-known fact that hy-
ponatraemia is associated with poor out-
come and extended-stay treatment, many 
doctors are not aware of the importance of 
reduced levels of plasma sodium concen-
tration. Hyponatraemia is an under-recog-
nized problem in the emergency depart-
ment (ED), and also insufficiently treated 
during the later treatment of patients. (3) 
Patients with hyponatraemia are an ex-
tremely heterogeneous group. (9-11) Early 
symptoms of hyponatraemia are vague and 
non-specific and can mimic the symp-
toms of neurological and psychiatric dis-
orders, especially in case of acute severe 
hyponatraemia. (4) It is very important to 
know the duration of severe hyponatrae-
mia. (11, 12) If it is within several hours 
specialists must consider conditions such 
as self-induced water intoxication associat-
ed with psychosis, and the use of 3,4-meth-
ylenedioxymethamphetamine (MDMA, or 
“ecstasy”). Clinical features include head-
ache, delirium, vomiting, seizures, coma, 
neurogenic pulmonary edema, brain 
swelling with risk of fatal herniation. The 
goal of therapy is 100-ml bolus of 3% saline 
three times as needed for severe symptoms 
(increase plasma sodium concentration 
by 4–6 mmol/litre in the first 6 hours). If 
the duration of severe hyponatraemia is 
1–2 days  present are conditions such as 
postoperative hyponatraemia, especially 
in women and hyponatraemia associated 
with intracranial disease. Clinical features 
could be headache, delirium, vomiting, 
seizures, coma, neurogenic pulmonary 
edema, brain swelling with risk of fatal 
herniation. The therapy goal is 100-ml bo-
lus of 3% saline three times as needed for 
severe symptoms and an increase plasma 
sodium concentration by 4–6 mmol/litre 
in the first 6 hours, but avoiding increas-
ing plasma sodium concentration by >10 
mmol/litre/day. (12) 
If the duration of severe hyponatraemia 
is unknown or ≥2 days, specialist must 
consider conditions associated with the 
high risk of the osmotic demyelination 
syndrome (plasma sodium concentration 
105 mmol/litre or less, hypokalemia, alco-
holism, malnutrition, liver disease). Clini-
cal features are malaise, fatigue, confusion, 
cramps, falls and seizures. The therapy 
goal is 100- ml bolus of 3% saline to in-
crease plasma sodium concentrations by 
4–6 mmol/litre in the first 24 hours, but 
avoiding increasing plasma sodium con-
centration by >8 mmol/litre/day. (11,12) 
Osmotic demyelination syndrome may 
develop when the plasma sodium concen-
tration is increased rapidly in outpatients 
who became hyponatraemia while drink-
ing normal amounts of water, as well as 
in hospitalized patients who became hy-
ponatraemia over 2 or more days. (12) Our 
data showed that in patients with acute hy-
ponatraemia (duration less than 12 hours) 
the levels of plasma sodium concentration 
(serum sodium) were very low, and these 
are the patients most often presented with 
stupor or coma or convulsions. Among the 
patients who developed neurological com-
plications, 80% did not survive, of which 
94% had acute hyponatraemia.
Hyponatraemia is usually a chronic con-
dition of reduced levels of serum sodium 
with symptoms of headache, nausea, vom-
iting, disorientation. (12) 
In this study we found that hyponatrae-
mia is present most frequently in patients 
of older age and often overlooked. (9) Our 
own results show that the percentage of 
patients who were examined in the emer-
gency department through the one month 
due to hyponatraemia is 7% of the total 
examined, lower than in the available lit-
erature data. (1) The most common was 
mild hyponatraemia, in patients with heart 
failure and iatrogenic caused by diuretic 
therapy (38%), which is consistent with 
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other studies. (5-7) The second most fre-
quent were patients with malignant disease 
(21%) and it is necessary to note that hy-
ponatraemia may be the first and only sign 
of inappropriate secretion of antidiuretic 
hormone (SIADH). (8) Neurological com-
plications, especially acute changes in mo-
tor skills and awareness, are an important 
factor in assessing outcomes. They indicate 
a high risk of death and require immediate 
reimbursement of hypertonic NaCl solu-
tion. (9) 
Hyponatraemia must be corrected gradu-
ally with the use of fluid restriction and 
slow infusions of 3% saline, furosemide, or 
by treatment of the underlying causes, and 
in some cases with use of urea or vasopres-
sin antagonists. (12)
CONCLUSION
In the ED caution should be exercised 
and the monitoring of patients with hy-
ponatraemia should be strengthened, 
especially in patients with malignant dis-
eases and chronic heart and renal disease. 
When the actual duration of hyponatrae-
mia is unclear it should be presumed to be 
chronic. Chronic hyponatraemia should 
be corrected gradually with the use of fluid 
restriction and slow infusions of 3% saline, 
furosemide, urea or vasopressin antago-
nists, or by treatment of the underlying 
cause. 
We should be alert to acute hyponatrae-
mia, especially in elderly patients with 
neurological manifestations. 
The presented data are an important con-
tribution to the better understanding of 
the epidemiology of hyponatraemia in the 
ED in Croatia. 
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